Medicare patient experience with vagus nerve stimulation for treatment-resistant depression

Journal of Medical Economics

Volumn 16, Issue 1, 2013, Pages 62-74

  Feldman, Rachel L ^a   Dunner, David L ^b   Muller, James S ^a   Stone, Devin A ^a  

^a Moran Company   (United States)

^b Center for Anxiety and Depression   (United States)

Author keywords

Health outcomes; Healthcare service utilization; Medicare beneficiaries; Medicare costs; Treatment resistant depression; Vagus nerve stimulation

Indexed keywords

ADULT; AGED; ARTICLE; COMORBIDITY; DISABILITY; ELECTROCONVULSIVE THERAPY; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; INTOXICATION; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; PREVALENCE; PSYCHOSIS; SUICIDAL IDEATION; TREATMENT RESISTANT DEPRESSION; VAGUS NERVE STIMULATION;

ADULT; AGED; COMORBIDITY; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; FEMALE; HEALTH SERVICES; HUMANS; INSURANCE CLAIM REVIEW; MALE; MEDICARE; MIDDLE AGED; UNITED STATES; VAGUS NERVE STIMULATION;

EID: 84868150752     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.724745     Document Type: Article

References (17)

1. Gaynes BN, Lux L, Lloyd S, et al. Nonpharmacologic interventions for treatment- resistant depression in adults. AHRQ Publication No. 11-EHC056-EF. Rockville, MD: Agency for Healthcare Research and Quality, 2011. http:// www.effectivehealthcare.ahrq.gov/reports/final.cfm. Accessed August 15, 2012
2. Martin JLR, Martin-Sanchez E. Systematic review and meta-analysis of vagus nerve stimulation in the treatment of depression: Variable results based on study designs. Eur Psychiatry 2012;27:147-55
3. Nemeroff CB, Mayberg HS, Krahl SE, et al. VNS therapy in treatment-resistant depression: Clinical evidence and putative neurobiological mechanisms. Neuropsychopharmacology 2006;31:1345-55
4. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR.*D report. Am J Psychiatry 2006;163:1905-17 (Pubitemid 44807782)
5. Russell JM, Hawkins K, Ozminkowski RJ, et al. The cost consequences of treatment-resistant depression. J Clin Psychiatry 2004;65:341-7
6. Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatmentresistant depression on health care utilization and costs. J Clin Psychiatry 2002;63:963-71 (Pubitemid 35388053)
7. Tierney JG. Treatment-resistant depression: Managed care considerations. J Manag Care Pharm 2007;13:S2-7
8. Cohen LJ, Allen Jr JC. Estimating the potential savings with vagus nerve stimulation for treatment-resistant depression: A payer perspective. Curr Med Res Opin 2008;24:2203-17
9. Greenberg P, Corey-Lisle PK, Birnbaum H, et al. Economic implications of treatment-resistant depression among employees. Pharmacoeconomics 2004;22:363-73 (Pubitemid 38609813)
10. Schachter SC, Schmidt D. Vagus nerve stimulation. London, England: Martin Dunitz, 2001
11. Bajbouj M, Merkl A, Schlaepfer TE, et al. Two-year outcome of vagus nerve stimulation in treatment-resistant depression. J Clin Psychopharmacol 2010;30:273-81
12. Nahas Z, Marangell LB, Husain MM, et al. Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clinl Psychiatry 2005;66:1097-104 (Pubitemid 41442274)
13. Marangell LB, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for major depressive episodes: One year outcomes. Biol Psychiatry 2002;51:280-287 (Pubitemid 34214993)
14. Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice guideline for the treatment of patients with major depressive disorder. Washington, D.C.: American Psychiatric Association, 2010
15. George MS, Rush AJ, Marangell LB, et al. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry 2005;58:364-73 (Pubitemid 41219704)
16. Rush JA, Marangell LB, Sackeim HA, et al. Vagus nerve stimulation for treatment-resistant depression: A randomized, controlled acute phase trial. Biol Psychiatry 2005;58:347-54 (Pubitemid 41219702)
17. US Food and Drug Administration. VNS Therapy System - p970003 www.accessdata.fda.gov/cdrh-docs/pdf/p970003.pdf. Accessed August 15, 2012